A Phase 1-2 Study of ABBV-453 in People With Multiple Myeloma

Full Title

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma

Purpose

Researchers want to find the best dose of ABBV-453 to treat multiple myeloma. The people in this study have multiple myeloma that may have a genetic change and make too much of the BCL2 protein. In addition, their cancer has not responded to treatment or has returned after treatment.

ABBV-453 works by blocking BCL2. By blocking this protein, ABBV-453 may cause cancer cells to die and stop or slow the growth of your cancer.

The researchers will assess ABBV-453 in combination with daratumumab and dexamethasone, or with daratumumab, pomalidomide, and dexamethasone. ABBV-453 is taken orally (by mouth).

Contact

For more information about this study or to see if you can join, please call Dr. Saad Usmani’s office at 646-608-4165.